Research Signal – Source date 2022-02-01
Immune checkpoint inhibitors have proved effective in treating cancers of the urinary system that have spread to other parts of the body, according to a 2022 systematic review. But using these medicines before an operation raises a different question: could they make kidney or bladder surgery harder? The review found 16 publications about treatment before surgery, yet the results conflicted and the operation itself was usually not examined directly.
That gap matters because evidence about treating cancer and evidence about what happens during a later operation answer different questions. The review identifies a concern worth investigating; it does not establish that preoperative treatment makes surgery more difficult, or how much it might affect an operation.
A different question before surgery
Immune checkpoint inhibitors are medicines that block checkpoint signals, which can act like brakes on immune activity. The review starts from their effectiveness against cancers that have spread, then asks whether using these drugs before kidney or bladder cancer surgery could affect the operation.
Those are not interchangeable claims. A treatment can be effective against metastatic disease without that fact answering whether an operation after treatment is easier, harder or unchanged. The authors describe increased surgical difficulty as a hypothesis that had been raised, rather than a settled effect.
How the authors searched
The authors followed systematic-review guidelines and searched PubMed for relevant literature available through 18 June 2020. They also looked at meeting abstracts from the American Society of Clinical Oncology, its genitourinary meeting, the European Society of Medical Oncology and the American Urological Association, covering 2015 to 2020.
Across those sources, they found 16 publications addressing immune checkpoint inhibitors before surgery in kidney and bladder cancers. That number counts publications; it should not be read as 16 comparable surgical trials or as a tally of patients. The abstract does not provide a patient total or establish a common study design for the publications. Their shared relevance was the question of treatment before surgery, even though the reports did not consistently answer the narrower question of surgical difficulty.
The search dates also set the review’s historical perspective. The paper appeared in February 2022, but the stated PubMed search ran through June 2020 and the meeting abstracts covered 2015–2020. The publication date does not add a later evidence cutoff.
The operation was usually not the outcome under study
The findings were conflicting. More fundamentally, the authors say surgical difficulties after checkpoint treatment were usually not approached directly. A publication about treatment before an operation may help describe the clinical context without measuring or comparing how difficult the operation was. So the existence of 16 relevant publications did not amount to 16 direct answers.
The abstract does not specify which operative measures were used, if any, or give outcome figures that would resolve the question. It also does not establish whether kidney and bladder operations differ in this respect. The careful conclusion is therefore limited: this review found a plausible surgical concern and a scattered, conflicting literature, but it cannot tell patients or surgeons whether preoperative treatment makes either type of operation harder.
How this could shape the future
If future studies directly compared operative outcomes, patients and surgeons considering checkpoint treatment before kidney or bladder surgery could better anticipate whether the treatment might complicate the operation. This review cannot answer that question because surgical difficulty was usually not studied directly. Better evidence could inform treatment and surgical planning; it would not, by itself, prove a treatment benefit or guarantee an easier, safer operation.
Key Sources
- Primary source: The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review ☆ .
DOI or Journal Page · Review or Meta-Analysis · 2022-02-01
Keep exploring